High-dose selective serotonin reuptake inhibitors in OCD: A systematic retrospective case notes survey

Journal of Psychopharmacology

Volumn 24, Issue 10, 2010, Pages 1439-1445

  Pampaloni, I ^a   Sivakumaran, T ^a   Hawley, C J ^b   Al Allaq, A ^a   Farrow, J ^a   Nelson, S ^a   Fineberg, N A ^a  

^a QUEEN ELIZABETH II HOSPITAL   (United Kingdom)

^b UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

Author keywords

high dose; OCD; SSRIs; treatment resistance

Indexed keywords

ARIPIPRAZOLE; CABERGOLINE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; DESMOPRESSIN; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; LITHIUM; MEMANTINE; MODAFINIL; PAROXETINE; QUETIAPINE; RISPERIDONE; SERTRALINE; TRAZODONE;

ADULT; APPETITE; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; CLINICAL EVALUATION; COGNITIVE THERAPY; CONFUSION; CONTROLLED STUDY; DIZZINESS; DROWSINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GILLES DE LA TOURETTE SYNDROME; HUMAN; HYPERPROLACTINEMIA; MALE; MONOTHERAPY; OBSESSIVE COMPULSIVE DISORDER; ONSET AGE; OUTPATIENT DEPARTMENT; PATIENT REFERRAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RIGIDITY; SEXUAL DYSFUNCTION; SIDE EFFECT; SWEATING; TIC; TREATMENT OUTCOME; TREMOR; URINARY FREQUENCY; WEIGHT GAIN; XEROSTOMIA; YALE BROWN OBSESSIVE COMPULSIVE SCALE;

ADULT; COGNITIVE THERAPY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG MONITORING; FEMALE; HUMANS; MALE; MEDICAL RECORDS; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; OUTPATIENT CLINICS, HOSPITAL; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; SEX CHARACTERISTICS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77958000506     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881109104850     Document Type: Article

References (27)

1. American Psychiatric Association (2007) Practice Guideline for the Treatment of Patients with Obsessive-Compulsive Disorder. Arlington, VA: American Psychiatric Association.
2. Baldwin, DS, Anderson, IM, Nutt, DJ, Bandelow, B., Bond, A., Davidson, JRT, et al. (2005) Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the Bristish Association for Psychopharmacology. J Psychopharmacol 19: 567-596.
3. Bejerot, S., Bodlund, O. (1998) Response to high doses of citalopram in treatment-resistant obsessive-compulsive disorder. Acta Psychiatr Scand 98: 423-424.
4. Bloch, MH, Landeros-Weisenberger, A., Kelmendi, B., Coric, V., Bracken, MB, Leckman, JF (2006) A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 11: 622-632 ; erratum in: Mol Psychiatry (2006) 11: 795 (epub 2006 Apr 4 Review). (Pubitemid 43989810)
5. British National Formulary (2006) Central Nervous System, Selective Serotonine Re-uptake inhibitors, BMJ group and RPS publishing.
6. Byerly, MJ, Goodman, WK, Christensen, R. (1996) High doses of sertraline for treatment-resistant obsessive-compulsive disorder. Am J Psychiatry 153: 1232-1233.
7. Dannon, P., Sasson, Y., Hirschmann, S., Iancu, I., Grunhaus, L., Zohar, J. (2000) Pindolol augmentation in treatment resistant obsessive compulsive disorder: a double blind placebo controlled trial. Eur Neuropsychopharmacol 10: 165-169.
8. De Almeida, A., Quarantini, L., Góis, C., Santos-Jesus, R., Miranda-Scippa, A., De Oliveira, I., et al. (2007) Obsessive-compulsive disorder: an open-label pilot trial of escitalopram. CNS Spectr 12: 519-524.
9. El Mansari, M., Blier, P. (2006) Mechanisms of action of current and potential pharmacotherapies of obsessive compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 30: 362-373.
10. Fineberg, N., Gale, T. (2005) Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int J Neuropsychopharmacol 8: 107-129 (epub 2004 Sep 28 Review).
11. Fineberg, N., Nigam, A., Sivakumaran, T. (2006) Pharmacologic strategies for treatment resistant OCD: a review of the evidence. Psychiatr Ann 36: 464-473.
12. Fineberg, N., Stein, D., Premkumar, P., Carey, P., Sivakumaran, T., Vythilingum, B., et al. (2006 a) Adjunctive quetiapine for SRIresistant obsessive compulsive disorder: a meta-analysis of randomised controlled treatment trials. Int Clin Psychopharmacol 21: 337-343.
13. Fineberg, N., Saxena, S., Zohar, J., Craig, K. (2007) Obsessive-compulsive disorder: boundary issues. CNS Spectr 2: 359-364, 367-375.
14. Fineberg, N., Tonnoir, B., Lemming, O., Stein, D. (2007) Escitalopram prevents relapse of obsessive-compulsive disorder. Eur Neuropsychopharmacol 17: 430-439.
15. Gillberg, C., Steffenburg, S. (1987) Outcome and prognostic factors in infantile autism and similar conditions: a population-based study of 46 cases followed through puberty. J Autism Dev Disord 17: 273-287.
16. Goddard, A., Shekhar, A., Whiteman, AF, McDougle, CJ (2008) Serotoninergic mechanisms in the treatment of obsessive-compulsive disorder. Drug Discov Today 13: 325-332 (epub 2008 Feb 14).
17. Goodman, WK, Price, LK, Rasmussen, SA, Mazure, C., Delgado, P., Heninger, GR, et al. (1989) The Yale Brown Obsessive Compulsive scale, I: validity, Arch. Gen. Psychiatry 46: 1012-1016.
18. Kent, J., Coplan, J., Lombardo, I., Hwang, D., Huang, Y., Mawlawi, O., et al. (2002) Occupancy of brain serotonin transporters during treatment with paroxetine in patients with social phobia: a positron emission tomography study with 11CMcN5652. Psychopharmacology (Berl) 164: 341-348.
19. NICE Guidelines (2006) Obsessive compulsive Disorder: core interventions in the treatment of obsessive compulsive disorder and body dysmorphic disorder full guideline. In: National Practice Guideline Number 31 developed by National Collaborating Centre for Mental Health, commissioned by the National Institute of Health and Clinical Excellence, published by the British Psychological Society and The Royal College of Psychiatry, pp 57-61.
20. Ninan, P., Koran, L., Kiev, A., Davidson, J., Rasmussen, S., Zajecka, J., et al. (2006) High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial. J Clin Psychiatry 67: 15-22.
21. Pallanti, S., Hollander, E., Bienstock, C., Koran, L., Leckman, J., Marazziti, D., et al. (2002) International Treatment Refractory OCD Consortium. Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol 5: 181-191.
22. Rabinowitz, I., Baruch, Y., Barak, Y. (2008) High-dose escitalopram for the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 23: 49-53.
23. Skapinakis, P., Papatheodorou, T., Mavreas, V. (2007) Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials. Eur Neuropsychopharmacol 17: 79-93.
24. Stein, D., Andersen, E., Tonnoir, B., Fineberg, N. (2007) Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. Curr Med Res Opin 23: 701-711.
25. Volkmar, F., Nelson, D. (1990) Seizure disorders in autism. J Am Acad Child Adolesc Psychiatry 29: 127-129.
26. Westenberg, H., Fineberg, N., Denys, D. (2007) Neurobiology of obsessive compulsive disorder: serotonin and beyond. CNS Spectrums 12 (Suppl. 3). 14-27.
27. Zhou, F., Liang, Y., Salas, R., Zhang, L., De biasis, M., Dani, J. (2005) Corelease of dopamine and serotonin from striatal dopamine terminals. Neuron 46: 65-74.